Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk

被引：11
|
作者：
Arnott, Clare [1 ,2 ,3 ]
Fletcher, Robert A. [1 ]
Neal, Bruce [1 ,4 ]
机构：
[1] Univ New South Wales, George Inst Global Hlth, Level 5,1 King St, Sydney, NSW 2042, Australia
[2] Royal Prince Alfred Hosp, Dept Cardiol, Sydney, NSW, Australia
[3] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[4] Imperial Coll London, Dept Epidemiol & Biostat, London, England
来源：
HEART FAILURE CLINICS | 2022年 / 18卷 / 04期
关键词：
SGLT2; inhibitors; Meta-analysis; Amputation; Fracture; TYPE-2; CANAGLIFLOZIN;
D O I：
10.1016/j.hfc.2022.03.008
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：645 / 654
页数：10
相关论文
共 50 条
  • [1] Sodium-Glucose Cotransporter-2 Inhibitors and the Risk of Amputation: What Is Currently Known?
    Misher, Anne
    Ampuero, Andrea
    Phan, Rebecca
    Aziz, Soma
    Ebong, Eti
    Braich, Judy
    Dyches, Kristin
    Southwood, Robin
    AMERICAN JOURNAL OF THERAPEUTICS, 2021, 28 (01) : E96 - E110
  • [2] Sodium Glucose Cotransporter 2 Inhibitors and Amputation Risk Achilles' Heel or Opportunity for Discovery?
    Bonaca, Marc P.
    Beckman, Joshua A.
    CIRCULATION, 2018, 137 (14) : 1460 - 1462
  • [3] Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
    Erythropoulou-Kaltsidou, Anastasia
    Polychronopoulos, Georgios
    Tziomalos, Konstantinos
    DIABETES THERAPY, 2020, 11 (01) : 7 - 14
  • [4] Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
    Lou, Yake
    Yu, Ying
    Duan, Junchao
    Bi, Sining
    Swe, Khaing Nyein Chan
    Xi, Ziwei
    Gao, Yanan
    Zhou, Yujie
    Nie, Xiaomin
    Liu, Wei
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2020, 11
  • [5] Sodium/Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis: An Example of Complementary Evidence for Rare Adverse Events
    Alkabbani, Wajd
    Pelletier, Ryan
    Gamble, John-Michael
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2021, 190 (08) : 1572 - 1581
  • [6] Sodium-Glucose Cotransporter 2 Inhibition and Cardiovascular Risk
    Liakos A.
    Bekiari E.
    Tsapas A.
    Current Cardiovascular Risk Reports, 2016, 10 (6)
  • [7] Sodium-glucose cotransporter-2 inhibitors use and the risk of gout: a systematic review and meta-analysis
    Lai, Shih-Wei
    Hwang, Bing-Fang
    Kuo, Yu-Hung
    Liu, Chiu-Shong
    Liao, Kuan-Fu
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [8] Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis
    Ruanpeng, Darin
    Ungprasert, Patompong
    Sangtian, Jutarat
    Harindhanavudhi, Tasma
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2017, 33 (06)
  • [9] Do sodium-glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real-world study
    Zhao, Bin
    Shen, Juan
    Zhao, Jun
    Pan, Hui
    JOURNAL OF DIABETES INVESTIGATION, 2021, 12 (08) : 1400 - 1407
  • [10] Sodium Glucose Cotransporter 2 Inhibitors
    White, John R., Jr.
    MEDICAL CLINICS OF NORTH AMERICA, 2015, 99 (01) : 131 - +
12345